Background: Obese breast cancer patients have a poorer prognosis than non-obese patients. We examined data from a large prospective cohort study to explore the associations of obesity with tumour pathology, treatment and outcome in young British breast cancer patients receiving modern oncological treatments.
introduction Obesity is a significant risk factor for post-menopausal breast cancer [1] . Studies indicate that obesity does not increase the risk of developing pre-menopausal breast cancer [2, 3] . However, there is increasing evidence that a high body mass index (BMI) is associated with poorer outcomes in breast cancer patients of all ages [4, 5] . A recent meta-analysis of 82 studies (not including these data) reported that obese women had poorer overall survival (OS) [hazard ratio (HR) 1.41] than non-obese women, with a more marked effect in pre-menopausal (OS HR 1.75) than postmenopausal women (OS HR 1.34) [4] .
The underlying reason for this association is not clear. Patients with a high BMI tend to present with larger tumours and some studies report more biologically adverse features including grade 3 tumours and nodal involvement in obese patients [6, 7] . Patients with a high BMI may also receive less effective treatment for early breast cancer. Ewertz et al. [7] reported that chemotherapy and endocrine therapy were less effective in patients with BMIs of ≥30 kg/m 2 and a recent review suggests that up to 40% of obese cancer patients may receive suboptimal chemotherapy doses [8] .
At least 26% of British women and 35% of American women are currently obese. These figures are predicted to increase to 43% and 52% by 2030 [9] . Furthermore, almost 50% of UK women aged 24-45 and 56% of American women aged 20-39 are overweight or obese [10, 11] . The POSH study is a prospective observational study of patients aged <41 years with breast cancer, diagnosed and treated in the UK [12] . This cohort of almost 3000 patients diagnosed between 2001 and 2008 represents, to the best of our knowledge, the largest prospective study of young breast cancer patients to date. Patients' height and weight were measured at registration. In this post hoc analysis, we describe the associations of BMI with tumour pathology, treatment, and outcome in these patients.
patients and methods
POSH is a multicentre prospective observational cohort study of young women diagnosed with breast cancer in the UK between 2000 and 2008 (http://www.southampton.ac.uk/medicine/research/posh.page).
The detailed study protocol was published in 2007 [12] . This study received approval from the South West Multi-centre Research Ethics Committee (MREC 00/6/69).
patients
Female patients were recruited from 127 UK hospitals. All patients were diagnosed with invasive breast cancer between 2000 and 2008 at an age of 40 years or younger, as previously described [12, 13] .
study variables and data sources
Details of personal characteristics, tumour pathology, disease stage, and treatment received were collected from medical records. Pathology and imaging data were verified with copies of original reports from sites. For patients treated with neoadjuvant chemotherapy, initial tumour diameter was derived from radiological reports. Family history and personal risk factors were collected using a questionnaire completed by participants at recruitment. BMI was calculated from height and weight measured at recruitment. Patients were stratified into World Health Organisation (WHO) defined BMI categories under or healthy weight (BMI<25 kg/m 2 ), overweight (25≤ BMI <30 kg/m 2 ), and obese (BMI ≥30 kg/m 2 ) [14] .
Detailed clinical follow-up data, including date and site of disease recurrence, were obtained from medical records at 6, 12 months, and at yearly intervals post-diagnosis until death or loss to follow-up. Patients were flagged in the NHS Medical Research Information Service to facilitate automatic notification of date and cause of death. This paper presents analyses conducted on follow-up data received until 22 October 2013.
tumour receptor status data ER, PR, and HER2 receptor status of primary tumours were primarily determined from routine diagnostic pathology tests. Hormone receptor levels equivalent to an Allred score of ≥3 were categorized as positive.
statistical analysis
Details of the target sample size (3000) are reported in the protocol [12] . The statistical analysis was conducted according to a pre-specified plan and as recommended by STROBE (STrengthening the Reporting of Observational Studies in Epidemiology) guidelines [15] . Analyses were carried out in STATA v11·2 on records with complete data (levels of missingness were reported). Summary statistics were used to describe the cohort. Where appropriate, the Pearson χ 2 , Kruskal-Wallis, or Mann-Whitney tests were carried out to identify any specific differences in the characteristic variables between BMI categories.
OS and distant disease-free interval (DDFI) were assessed using the Kaplan-Meier curves. These were defined as time from date of invasive breast cancer diagnosis to death from any cause (OS), and to distant relapse or death from breast cancer (DDFI). Patients who had not experienced an event at the time of analysis were censored at their date of last follow-up. As the effect of ER status on survival varies over time, the multi-variable analyses (MVA) models were stratified by ER status [13, 16] . MVA were carried out using the Cox regression to adjust for age at diagnosis and tumourrelated factors known to affect prognosis (grade, total tumour diameter, nodal status, and HER2 status) according to our original statistical analysis plan. Following our publication of data demonstrating that race has an independent effect on the outcome of patients in the POSH cohort, we carried out additional MVA including race as an adjustment factor [17] .
results
The POSH study recruited 3095 patients across England (2695), Scotland, Wales, and Northern Ireland. After excluding 252 trial participants (supplementary Figure S1 , available at Annals of Oncology online), 2843 patients were included in this analysis.
One thousand five hundred and twenty-six patients (53.7%) were under or healthy weight (U/H) including 36 patients with a BMI of ≤18.5 kg/m 2 , 784 (27.6%) were overweight, and 533 (18.7%) were obese. The median age was significantly lower in U/H patients than overweight (U/H 36 versus Ov 37, P = 0.0063) and obese patients (U/H 36 versus Ob 37, P = 0.0322). The median follow-up was 5.87 years for the entire cohort but was significantly longer in U/H patients than overweight (U/H 5.98 versus Ov 5.79, P = 0.0023) and obese patients (U/H 5.98 versus Ob 5.62, P = 0.0014). Table 1 demonstrates patient demographics and breast cancer risk factors in the different BMI categories.
pathology
The median tumour size was significantly higher in obese and overweight patients than U/H patients Ob 26 mm versus U/H 20 mm, P < 0.001. Ov 24 mm versus U/H 20 mm, P < 0.001). Obese patients and overweight patients had significantly more grade 3 tumours (Ob 63.9% versus U/H 59.0%, P = 0.048; Ov 63.6% versus U/H 59.0% P = 0.034) and node-positive tumours (Ob 54.6% versus U/H 49.0%, P = 0.027; Ov 54.2% versus U/H 49%, P = 0.019) than U/H patients. ER-negative tumours were significantly more frequent in obese patients than U/H patients (40.1% versus 31.7%, P < 0.0001), whereas the proportion of HERpositive tumours was similar across patient groups (P = NS). ER/PR/HER2 triple negative tumours were more frequent in obese than U/H (25.0% versus 18.3%, P = 0.001) or overweight patients (25% versus 19.4%, P = 0.020) ( 
follow-up and survival
At the time of analysis, length of follow-up ranged from 1 month to 13 years (median 5.87 years). Only 87 patients (3.1%) had been lost to follow-up. Isolated local relapse events were few and will be explored in detail in a subsequent article [13] . DDFI at 5-and 8-years were significantly lower in obese (HR 1.44, P < 0.001) and overweight patients (HR 1.29, P = 0.003) than in U/H patients (5- year DDFI: U/H 78.6%, Ov 72.9%, Ob 71.3%; 8-year DDFI U/H 73.0%, Ov 68.1%, Ob 63.5%) (Figure 1) . OS rates at 5-and 8-years were also significantly lower in obese (HR 1.65, P < 0.001) and overweight patients (HR 1.41, P < 0.001) (5-year OS: U/H 86.0%, Ov 78.9%, Ob 78.8%; 8-year OS: U/H 76.3%, Ov 68.2%, Ob 62.7%) ( Figure 2 ). MVA with adjustment for age at diagnosis, tumour grade, size, nodal status, and HER2 status ( Table 3) indicated that obesity was a significant independent predictor of both OS (HR 1.36, P = 0.005) and DDFI (HR 1.25, P = 0.033). On separate MVA of ER-positive and ER-negative patients, obesity was an independent prognostic factor in ER-positive patients (OS HR 1.47, P = 0.006 and DDFI HR 1.39, P = 0.010) but not ER-negative patients. Being overweight was also a significant independent predictor of inferior OS (HR 1.29, P = 0.010), and DDFI (HR 1.21, P = 0.042) but for the whole cohort only; significance was lost in this group on separate MVA of ER-positive and ERnegative patients.
discussion
The POSH study is the largest prospective study of obesity and breast cancer outcome in pre-menopausal women to date [13] . In keeping with the general population of UK 24-45 year olds, 46.3% of our cohort was/patients were overweight or obese at recruitment [10] . The POSH cohort is representative of the general UK breast cancer population for this age group in terms of other characteristics [13] .
This study confirms previous studies and meta-analyses results showing that obesity is associated with poorer OS in comparison with U/H patients, with an unadjusted HR for OS of 1.65. The POSH data represent a young patient group, who are less likely to have significant co-morbidities than older patients. As described previously, 94% of deaths in this cohort were due to breast cancer [13] . Our data also support other studies which have found inferior DDFI associated with obesity [4, 5] suggesting that the adverse effect of obesity in this young patient group is due to breast cancer recurrence rather than obesity-associated non-breast cancer mortality.
Our data confirm previous reports of more advanced disease in obese patients [7] . All patients in our study were below the minimum age for UK national breast screening, over 98% presented with symptomatic tumours. The increasing mean tumour diameter and increased nodal involvement in patients with a higher BMI may be entirely due to body habitus but could also represent delays in self-referral or referrals from primary to secondary care.
Our data also confirm previous reports that obese patients have more biologically adverse tumours, with increased proportions of grade 3, ER-negative and triple negative tumours.
The reason for this is unclear, but obesity is a subclinical inflammatory state and activated macrophages in adipose tissue producing pro-inflammatory mediators could potentially affect the tumour micro-environment [18] . Obesity is also associated with raised levels of adipocytokines including leptin, and insulin/ insulin-like growth factor which have direct mitogenic/ anti-apoptotic activity [19] .
Our MVA results support other studies showing obesity to be an independent poor prognostic factor reducing both DDFI? and OS in unselected breast cancer patients adjusted for pathological features [6, 7, 20] . This effect could be due to direct biological effects of obesity on the tumour but obesity may influence the delivery of effective breast cancer treatments.
Ewertz et al. [7] suggested reduced use of chemotherapy in non-age selected obese patients as a potential explanation for this outcome. However, we found greater overall usage of anthracyline/ taxane therapy in the obese patient group. Most cytotoxics are dosed according to body surface area, a formula that was not designed for use at extremes of weight, and optimum dosing of chemotherapy in obese individuals is unresolved. A recent review indicated that up to 40% of obese cancer patients receive capped chemotherapy doses [8] .
We do not have complete data on chemotherapy dose intensity for the entire study cohort but analysis of chemotherapy prescription records for the 77 POSH participants treated with adjuvant chemotherapy at the Southampton Oncology Centre indicates that obese patients were significantly more likely to receive a dose delay than healthy weight patients (33.3% versus 5.9%, P = 0.0068, data not shown). Gouerant et al. [21] also reported reduced dose intensity of docetaxel among obese patients.
We found that obesity is an independent prognostic factor in ER-positive but not ER-negative young breast cancer patients. Smaller numbers in our ER-negative group reduces power, but we found no dose-response relationship for ER-negative patients. while there is one for the ER positive patients. Although previously published series reported no evidence that breast cancer outcome differs by hormone receptor, our finding is supported by the recently presented data from 80 trials showing a significant association between obesity and prognosis in pre-menopausal and perimenopausal women with ER-positive disease only [5, 22] . More specifically, Sparano et al. [23] have shown an association between obesity and inferior outcome in ER-positive, HER 2-negative disease only.
An analysis of the ABCSG-12 trial reported that BMI significantly influenced the efficacy of anastrozole plus goserelin in premenopausal patients but did not influence the prognosis of patients treated with tamoxifen plus goserelin [24] . In the POSH cohort, 88.6% of ER-positive patients received tamoxifen, but the use of ovarian suppression was limited (17.2% medical suppression, 22.2% oophorectomy; not mutually exclusive). Our data could suggest that tamoxifen without ovarian suppression may be less effective in high BMI patients. Our study did not collect data on adherence, so we cannot exclude the possibility of an association between obesity and reduced tamoxifen adherence in young women This study is strengthened by its prospective nature and use of BMIs calculated from objective measurements of height/ weight at registration. Many previous reports have relied on self-reported height/weight and some analyses have been compromised by BMI data being available only for patients who received chemotherapy [25] . Data from interventional clinical trials may be biased by selection of healthier obese patients than the general population. We have also consistently used standard WHO definitions of BMI categories [14] ; some publications have used alternative definitions and this may have influenced meta-analyses. Higher proportions of overweight and obese black or American African groups compared with Caucasian women may lead to confounding [26] . Race is an independent prognostic factor for recurrence and OS in this patient cohort [17] , but the addition of race as an adjustment factor in our MVA (Table 3 ) did not alter our finding that obesity is an independent prognostic factor in ER-positive patients (OS HR 1.47, P = 0.006).
In conclusion, our data provide important confirmatory evidence that obesity at diagnosis is associated with poor outcome in young British breast cancer patients and is an independent prognostic marker in ER-positive patients. Further research is needed to optimize treatments for this patient group.
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